Buy Tirzepatide

Tirzepatide (also known as GIP/GLP-1 Dual Agonist) is available directly from New-U Research Compounds at https://new-u.io/peptide/tirzepatide. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

Tirzepatide starts at $160 for a 10-vial research pack (5mg per vial) at New-U Research Compounds, with 10 pack sizes available. Orders over $300 ship free.

Yes. Every Tirzepatide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

Tirzepatide ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, Tirzepatide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

Tirzepatide, dual GIP/GLP-1 receptor agonist with imbalanced agonism favouring GIP, with body-composition reductions reported in published research. New-U supplies Tirzepatide as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the Tirzepatide research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for Tirzepatide are described in research-model terms only. New-U Research Compounds supplies Tirzepatide strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Yes. Tirzepatide can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

Tirzepatide ships in 10-vial research packs as standard, in 10 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade Tirzepatide, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/tirzepatide.

Tirzepatide is a dual GIP and GLP-1 receptor agonist (a "twincretin") — the peptide best known as the active ingredient in Eli Lilly's Mounjaro and Zepbound. Tirzepatide is the research-grade form of this tirzepatide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is NOT Mounjaro or Zepbound, is not an approved medicine, and is not for human use.

In the published literature tirzepatide activates both the GIP and GLP-1 receptors, combining their satiety, insulin-secretion and adipose-tissue effects — which is why it is described as a "dual incretin" agonist. These are mechanisms reported for the molecule in research, not human-use guidance; Tirzepatide is supplied for laboratory research only.

Not exactly — tirzepatide is a DUAL agonist: it activates both the GIP receptor and the GLP-1 receptor, whereas semaglutide activates GLP-1 alone. That second (GIP) arm is the key structural difference. Tirzepatide is the research-grade tirzepatide peptide, supplied for research use only.

It is the same active peptide (tirzepatide) but NOT the same product. Mounjaro and Zepbound are FDA-approved, prescription, sterile finished pharmaceuticals made under cGMP. Tirzepatide is an unapproved, research-grade lyophilised powder sold for laboratory research only — not for human consumption and not a substitute for any prescribed medication.

Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. The added GIP receptor activity drives additional satiety and adipose-tissue effects, producing larger weight loss and HbA1c reductions in published research.

It is a full agonist at GIPR (comparable potency to native GIP) but biased at GLP-1R, favouring cAMP signalling over β-arrestin recruitment. The asymmetry preserves the GIP arm while reducing the receptor desensitisation that can blunt long-term efficacy at GLP-1R.

Keep the lyophilised powder at −20 °C in the freezer. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Avoid repeated freeze-thaw cycles, which can damage the fatty acid tail and reduce potency.

Published trials of the reference drug (the SURMOUNT-4 withdrawal study of tirzepatide) report that stopping a GIP/GLP-1 receptor agonist leads to a return of appetite and substantial regain of lost weight over the following months, as the dual receptor stimulation that suppressed appetite and slowed gastric emptying ends. Those findings describe the approved medicine in human studies — Tirzepatide is an unapproved research-grade peptide for laboratory research only and is not for human use.